[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pseudomonas-aeruginosa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pseudomonas-aeruginosa":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,66,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861",false,"NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[25,26,27,28,29,30],"Pseudomonas Infections","Pseudomonas Aeruginosa","Prognosis","Drug Resistance, Multiple, Bacterial","Antibacterial Agents","Beta-lactam Antibiotics","RECRUITING","2026-04-29",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2025-03-11",{"date":39,"type":21},"2027-01",{"name":41,"class":42},"Centre Hospitalier Régional d'Orléans","OTHER",48,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100579297","pathobiomes-in-gut-of-critically-ill-patients-100579297","NCT06822465","Pathobiomes in Gut of Critically Ill Patients","Inclusion Criteria:\n\n* Any ethnicity\n* Age \\> 18 years and \\\u003C 85 years\n\nExclusion Criteria:\n\n* A known history of HIV\u002FAIDS\n* Active pregnancy\n* Are incarcerated will be excluded from the study.",true,"85 Years",{"count":53,"type":21},100,"Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb to multi-organ failure and septicemia secondary to an invasive nosocomial infection. The sequelae of shock, hypoxia, and parental nutrition result in injury to the intestinal mucosa, changes in gut permeability, and failure of intestinal defense mechanisms. These conditions put patients at risk for infection and multiple organ failure secondary to the translocation of enteric bacteria, initiating a systemic release of inflammatory mediators-a process that has been termed gut-derived sepsis.\n\nIntestinal P. aeruginosa senses host factors released during stress and responds by activating its virulence gene machinery. As such, the presence of a highly activating intestinal milieu serves to induce virulence in strains of P. aeruginosa and this correlates to the severity of a patient's illness. While the host-pathogen interaction is a dynamic process, the study expects that as a patient's illness worsens or resolves over time, the \"virulence-activating\" properties of their intestinal milieu will change accordingly. This study will conduct a prospective observational trial in a population of critically ill patients at the Universtiy of Chicago Medical Center. This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The study also plans to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.",[26],"2026-01-29",{"date":58,"type":35},"2026-02-02",{"date":60,"type":35},"2024-12-19",{"date":62,"type":21},"2029-12",{"name":64,"class":42},"University of Chicago",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":65},"100388254","isolation-of-human-recombinant-therapeutic-monoclonal-anti-pseudomonas-antibodies-100388254","NCT04335383","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial","ABAC-IBS","Inclusion Criteria:\n\n* Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)\n* Patient with weight ≥ 32kg.\n* With a follow-up visit at Grenoble University Hospital with a blood sampling for its care\n* Having given its written no objection to participate in the prospective phase of this project\n\nExclusion Criteria:\n\n* Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)",{"count":75,"type":21},30,"Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.\n\nThe aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.",[26,78],"Multi-antibiotic Resistance",[80,81],"Pseudomonas aeruginosa","monoclonal antibody","2025-11-17",{"date":84,"type":35},"2025-11-20",{"date":86,"type":35},"2020-10-05",{"date":88,"type":21},"2026-10",{"name":90,"class":42},"University Hospital, Grenoble",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":65},"100597314","monotherapy-vs-combination-therapy-for-bone-infections-caused-by-pseudomonas-aeruginosa-100597314","NCT07056881","Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Diagnosis of osteitis or osteomyelitis due to Pseudomonas aeruginosa\n* Isolation of Pseudomonas aeruginosa from at least one deep, sterile sample (e.g., bone biopsy, joint aspiration)\n* Imaging findings consistent with osteomyelitis (MRI, CT scan, or X-ray)\n\nExclusion Criteria:\n\n* No isolation of Pseudomonas aeruginosa\n* No imaging evidence suggestive of osteomyelitis\n* Patients under 18 years of age",{"count":98,"type":21},300,"This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa. It includes 300 adult patients who had this type of infection confirmed by lab tests and medical imaging. The goal is to find out if using just one antibiotic is as effective as using two, while also looking at side effects, the need for more surgery, antibiotic resistance, and overall antibiotic use.",[101,25,26,102],"Osteomyelitis","Bacterial Infections","2025-06-30",{"date":105,"type":35},"2025-07-09",{"date":107,"type":35},"2025-04-11",{"date":109,"type":21},"2026-04-15",{"name":111,"class":42},"Centre Hospitalier de Saint-Denis"]